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ABSTRACT 
Introduction Patients with Alzheimer’s disease (AD) show heterogeneity in profile of cognitive 
impairment. We aimed to identify cognitive subtypes in four large AD cohorts using a data-driven 
clustering approach.  
Methods We included probable AD dementia patients from the Amsterdam Dementia Cohort (ADC, 
n=496), Alzheimer’s Disease Neuroimaging Initiative (ADNI, n=376), German Dementia Competence 
Network (DCN, n=521), and University of California, San Francisco (UCSF, n=589). 
Neuropsychological data were clustered using Nonnegative Matrix Factorization. We explored clinical 
and neurobiological characteristics of identified clusters. 
Results In each cohort, a two-clusters solution best fitted the data (cophenetic correlation >.9): One 
cluster was memory-impaired, and the other relatively memory-spared. Pooled analyses showed that 
the memory-spared clusters (29-52% of patients) were younger, more often APOE e4 negative, and 
had more severe posterior atrophy compared to the memory-impaired clusters (all p<.05). 
Conclusions We could identify two robust cognitive clusters in four, independent large cohorts with 
distinct clinical characteristics.  
 
ABBREVIATIONS ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, APOE = Apolipoprotein E, CSF = cerebrospinal fluid, DCN = German 
Dementia Competence Network, MMSE = Mini-Mental State Examination, MRI = magnetic 
resonance imaging, MTA = medial temporal lobe atrophy, NMF = nonnegative matrix factorization, 
PA = atrophy of the posterior cortex, UCSF = University of California, San Francisco. 
 
HIGHLIGHTS (max 85 characters including spaces per point) 
 Alzheimer’s disease (AD) is a heterogeneous disorder (54) 
 We identified two cognitive AD subtypes in four cohorts with a data-driven approach (82) 
 Non-amnestic AD is associated with distinct neurobiological characteristics (77) 
 
RESEARCH IN CONTEXT  
1.Systematic review: Alzheimer’s disease (AD) is characterized by cognitive heterogeneity. We 
searched PubMed for clinical and neurobiological heterogeneity in AD profiles, and for data-driven 
approaches used to identify AD subtypes based on neuropsychological test scores. Several studies 
demonstrated the potential of clustering methods to identify cognitive AD subtypes. Identified 
subtypes showed distinct clinical characteristics. However none of the previous studies tested the 
generalizability of the cluster solutions, since those results were based on single-cohort studies. 
2. Interpretation: In four large AD cohorts, we consistently identified two cognitive clusters using 
Nonnegative Matrix Factorization of neuropsychological test scores. In each cohort one cluster most 
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prominently showed memory-impairment, and the other cluster was relatively memory-spared. These 
clusters were associated with distinct clinical characteristics. 
3. Future directions: Future research should aim to further study the underlying biological disease 
mechanisms that cause a non-memory AD phenotype.  
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1. Introduction 
 
Alzheimer’s disease (AD) dementia is characterized by progressive cognitive impairment in multiple 
cognitive domains, e.g. memory, language, visuospatial and executive functioning, and attention. 
Typically, AD is characterized by early and prominent memory loss.[1] A minority of patients has a 
prominent and relatively focal cognitive presentation, such as logopenic-variant primary progressive 
aphasia (lvPPA), posterior cortical atrophy (PCA), or a behavioural/dysexecutive subtype.[2-5] 
Atypical variants have been associated with specific demographic, genetic, and 
neuroimaging/biomarker findings that are distinct from those of typical amnestic patients (e.g. age at 
onset, apolipoprotein E [APOE] genotype, distribution of cortical atrophy, hypometabolism, tau 
deposition, cerebrospinal fluid biomarker concentrations, and pathological findings).[6-10] However, 
even patients who do not display a defined subtype also show considerable variation in patterns of 
cognitive impairment. Earlier studies demonstrated the potential to capture cognitive heterogeneity in 
AD using a data-driven clustering approach.[11-14] Studies differed in sample size, clinical diagnosis 
of included patients, available neuropsychological test results, available neurobiological characteristics 
to compare clusters with, and clustering technique. This has resulted in different numbers of clusters, 
with different cognitive and neurobiological characteristics. Although those studies were clearly 
suggestive of variability in underlying pathological mechanisms, it is difficult to generalise the 
findings, since they result from single studies that show considerable variability in patient population 
and methodological approaches. 
 
In the present study, we aimed to identify cognitive subtypes and to study whether these subtypes 
could be replicated in three independent AD dementia cohorts. For the identification of cognitive AD 
subtypes, we used Nonnegative Matrix Factorization (NMF).[15-18] Based on earlier descriptions of 
cognitive heterogeneity, we expected NMF to identify at least a cluster including patients with typical 
amnestic AD, and one or more other clusters including patients with non-amnestic features.[15-18]  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
N.M.E. Scheltens ea. – Cognitive AD subtypes identified using NMF 
 5 
2. Methods 
 
2.1. Patients 
We selected AD patients from four large cohorts: The Amsterdam Dementia Cohort (ADC), the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI), the German Dementia Competence Network 
(DCN), and the University of California, San Francisco Memory and Aging Center research cohort 
(UCSF). Patients were selected based on 1) clinical diagnosis of probable AD dementia, 2) availability 
of neuropsychological test results, and 3) Mini-Mental State Examination (MMSE) score >16/30.[19] 
In the ADC and UCSF cohort, patients with focal presentations lvPPA, PCA, and the 
behavioural/dysexecutive subtype of probable AD dementia were included, while such subjects were 
explicitly excluded from participation in the ADNI and DCN studies.  
 
From the ADC we selected 496 patients with probable AD.[20] Patients visited the outpatient memory 
clinic of the VU University Alzheimer Center between 2008 and 2013. Standard dementia screening 
included for most patients medical history and medication use, physical and neurological examination, 
extensive neuropsychological evaluation, screening laboratory tests, APOE genotyping, magnetic 
resonance imaging (MRI), and lumbar puncture (LP). In the ADC, level of education was defined 
according to a rating scale ranging from 1 (low, primary school not finished) to 7 (high, university 
degree).[21] All participants provided written informed consent to use their clinical data for research 
purposes. The local ethical committee approved the study. 
 
From the ADNI database (adni.loni.usc.edu) we selected 376 probable AD patients. Patients were 
recruited in over 50 sites across the U.S. and Canada (www.adni-info.org). Standard workup included 
medical history, physical and neurological examination, extensive neuropsychological evaluation, 
screening laboratory tests, APOE genotyping, neuroimaging including MRI, and LP. For the present 
study, we used data of screening and baseline visits, acquired for ADNI-1 or ADNI-2 between 2005 
and 2013. All patients gave written informed consent at screening.  
 
From the DCN cohort database (http://www.kompetenznetz-demenzen.de) we selected 521 probable 
AD patients.[22] The DCN is a collaboration of fourteen specialized German memory clinics from 
university hospitals. All patients were offered a uniform dementia screening at first visit between 2003 
and 2007, including medical history, physical and neurological examination, extensive 
neuropsychological evaluation, screening laboratory tests, MRI scan, and LP. The DCN study protocol 
was approved by the Institutional Review Boards of all participating study centres.[22] All patients, or 
their legal guardians, provided written informed consent. 
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From the UCSF research cohort we selected 589 probable AD patients.[23] Patients were either seen 
in the outpatient memory clinic, or for a research assessment in the UCSF Alzheimer’s Disease 
Research Center. All patients were assessed at first visit between 1998 and 2013. Standardized 
dementia screening included medical history, physical and neurological examination, 
neuropsychological evaluation, screening laboratory tests, APOE genotyping, and neuroimaging 
including MRI. A core screening neuropsychological battery was performed in both the clinical and 
research settings. All patient and informants provided written informed consent. Surrogate consent 
was accepted when patients lacked capacity to provide consent themselves. The local medical ethical 
committee approved the study. 
 
2.2 Neuropsychological tests 
Neuropsychological data included tests covering the major cognitive domains in each cohort, but the 
exact composition of neuropsychological test batteries differed across cohorts. Neuropsychological 
tests included for analysis in this study are shown in supplementary table 1. The number of missing 
neuropsychological values differed across cohorts and within neuropsychological test batteries (on 
average 20% in ADC, 27% in ADNI, 1% in DCN, 12% in UCSF). Main reasons for missingness are 
practical reasons unrelated to the data (random). In part of the cases however, tests could not be 
finished due to cognitive impairment, whereas scoring differed across cohorts and between tests (i.e. 
assignment of missing value or minimum score). The clustering technique NMF does not allow for 
missing data or negative values. In order to reduce selection bias, we did not select patients based on 
completeness of datasets, but we completed the datasets using a multiple imputation approach that is 
commonly used as a reliable method to estimate missing data. 
We imputed missing neuropsychological data using R package Multivariate Imputation by Chained 
Equations (MICE, version 2.25).[24,25] MICE estimates missing neuropsychological values by 
predicting these values from the relationships with other neuropsychological variables. We also 
included predictors age, gender, MMSE, and when available education, duration of complaints, 
Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-cog) or Cambridge Cognitive 
Examination (CAMCOG) or Cognitive Dementia Rating (CDR) sum of boxes in the imputation 
model. We ran MICE 50 times per cohort, resulting in 50 imputed datasets for each cohort. For further 
analyses, we included pooled measures over the 50 derived imputed datasets per cohort.[26,27] We 
inverted values when appropriate, so that for all tests lower scores reflect worse cognitive impairment. 
Next, the imputed neuropsychological data were normalized and scaled to include only positive values 
(0-1). 
 
2.3 MRI characteristics 
MRI characteristics were available for patients from the ADC, ADNI, and DCN cohorts.  
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For the ADC cohort, imaging data was obtained on a 1.5T or 3T scan. Visual ratings of medial 
temporal lobe atrophy (MTA; range 0-4[28]), posterior atrophy (PA; range 0-3[29]), and white matter 
hyperintensities (WMH; range 0-3[30]) were performed by an experienced neuroradiologist. For 
ADNI, a structural MRI 1.5T scan was performed on screening or baseline visit.[31] Image processing 
has been done with cortical reconstruction and volumetric segmentations using FreeSurfer 4.3 
(surfer.nmr.mgh.harvard.edu/).[32] Hippocampal and WMH volumes were downloaded from the 
ADNI website (ida.loni.usc.edu/).[33] For the DCN cohort, MRI data was obtained from multiple 1.5T 
scanners with standardized MRI acquisition guidelines across centres.[22,34] PA and WMH were 
scored by experienced neuroradiologists using a visual rating scale in which higher scores reflect more 
severe abnormalities (range 0-3). Furthermore, hippocampal volumes were measured using FMRIB’s 
Integrated Registration and Segmentation Tool (FIRST) from the FMRIB Software Library (FSL) 
package of tools.[35,36] For all atrophy measurements, we included the mean of left and right 
hemisphere.  
 
2.4 APOE e4 genotype 
APOE e4 genotype was available in the ADC (n=448; 90%), ADNI (n=196; 52%), DCN (n=397; 
76%), and UCSF (n=175; 30%) cohorts. We dichotomised APOE e4 genotype according to the 
presence or absence of one or more APOE e4 alleles. APOE genotype was assessed using the Light 
Cycler APOE mutation detection method (Roche Diagnostics GmbH, Mannheim, Germany) in the 
ADC. For ADNI, APOE alleles were genotyped using DNA extracted by Cogenics. For the DCN, 
APOE genotype was assessed using Qiagen blood isolation kit (Qiagen, Hilden, Germany). For UCSF, 
APOE genotype was conducted using a TaqMan Allelic Discrimination Assay on an ABI 7900HT 
Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). 
 
2.5 AD biomarkers 
Cerebrospinal fluid (CSF) markers amyloid-beta1-42 (Abeta1-42), and total tau (tau) were available for 
ADC (n=389; 79%), ADNI (n=102; 27%), and DCN (n=193; 37%). CSF biomarkers were assessed 
using Sandwich ELISAs (Fujirebio, Gent, Belgium) in ADC and DCN[37], and Multiplex xMAP 
Luminex platform (Luminex Corp, Austin, TX) with Fujirebio immunoassay kit–based reagents 
(INNO-BIA Alzbio3; Fujirebio, Ghent, Belgium) in ADNI. CSF biomarkers were considered positive 
for AD when tau / Abeta1-42 ratio was > 0.52 [38]. Pittsburgh compound B position emission 
tomography visual reading results (i.e. positive or negative) were available for the UCSF cohort 
(n=52; 9%).  
 
2.6 Statistical analysis 
For statistical analyses, we used RStudio for Mac version 3.2.2 (Integrated Development for R. 
RStudio, Inc., Boston, MA, http://www.rstudio.com). Clustering was performed with the R package 
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Nonnegative Matrix Factorization (NMF, version 0.20.6).[39] Clustering is a data-driven method to 
divide a heterogeneous set of objects (patients) in subgroups that are more homogeneous in terms of 
characteristics provided as input for the clustering (neuropsychological test results). NMF is a dual-
clustering approach, meaning that clustering includes two parallel steps (illustrated in figure 1). 
Firstly, neuropsychological test results are grouped together into neuropsychological profiles 
(‘components’), and neuropsychological tests that determine these components can be identified by 
their component loading. Secondly, patients are grouped together based on the fit of their 
neuropsychological profile to the neuropsychological summary component. The optimal number of 
clusters is based on the most consistent assignment of patients to the identified cognitive profiles in 
the multiple runs of NMF. The stability of the cluster solution is assessed with the cophenetic 
correlation coefficient, that measures how consistently tests and subjects are assigned to a given 
component, ranging between 0 and 1 (i.e. no stability to stable cluster solution). For each cohort, we 
determined the optimal number of clusters based on the highest cophenetic correlation coefficient for 2 
to 9 cluster solutions.[15] We used the ‘nonsmooth’ NMF algorithm that introduces an intermediate 
smoothing matrix to enhance sparsity of the clusters.[40]  
Characterization of identified clusters in terms of neuropsychological profile was based on the most 
strongly loading neuropsychological tests.[17] For characterization of identified clusters in terms of 
demographic, clinical, and neurobiological characteristics, we analysed age, sex, education, disease 
duration reported by the patient, MMSE, APOE e4 genotype, CSF biomarkers, MRI atrophy, and 
WMH measurements using χ2, t-tests, or Kruskal Wallis tests where appropriate. These analyses were 
performed for each cohort separately. In addition, for each cluster we pooled the patient characteristics 
over the cohorts in order to compare them for the total sample. To this end we Z-transformed variables 
with different scales (i.e. education, CSF biomarkers, and MRI biomarkers) before pooling. When 
atrophy of the hippocampus and the posterior cortex was measured using a visual rating scale in which 
higher scores reflect more severe atrophy, the normalized scores were inverted so that higher scores 
reflect less atrophy in all cohorts and the pooled sample.
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3. RESULTS 
 
3.1 Cohort characteristics 
Characteristics of all cohorts are summarized in table 1. On average, patients were 719 years old, 
with the ADC being the youngest cohort. 54% of patients were female, ranging from 44% (ADNI) to 
60% (DCN). Patients were mildly-to moderately demented, with an average MMSE varying between 
cohorts from 22-24. Roughly two thirds of patients were APOE e4 carrier, ranging from 57% (UCSF) 
to 67% (ADC).  
 
3.2 NMF clusters of cognitive subtypes 
NMF is a dual-clustering approach; first, neuropsychological tests are grouped into components, and 
second patients are clustered based on the fit of their neuropsychological profiles to the profiles of the 
identified neuropsychological components, taking the load of each test to the component into account. 
NMF showed that within each cohort, the optimal number of clusters was two, as the solution with 
two clusters showed the strongest cophenetic correlation (>.90).  
 
Results of the clustering of tests are shown in figure 2. In the ADC, one neuropsychological 
component mainly included memory tests Rey auditory verbal learning test (RAVLT) immediate and 
delayed recall. The other component included mainly non-memory tests trail making test (TMT)-A 
and TMT-B, and fragmented letters. In the ADNI cohort, one neuropsychological component mainly 
included memory tests logical memory immediate and delayed recall, and RAVLT delayed recall. The 
other component mainly included non-memory tests TMT-A and TMT-B. In the DCN cohort, one 
neuropsychological component included mainly memory tests logical memory immediate and delayed 
recall, word list immediate and delayed recall of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD), and Rey figure recall. The other component included mainly non-
memory tests TMT-A, TMT-B, clock drawing, and CERAD figure copy. In the UCSF cohort, one 
neuropsychological component included mainly memory tests figure recall, and the California verbal 
learning test (CVLT) delayed recall. The other component included mainly non-memory tests 
modified trails, design fluency, and stroop interference.  
 
Patients were assigned to either of two clusters based on the fit of their neuropsychological test results 
to the memory or non-memory component in each cohort (figure 3). Across all cohorts, the memory 
clusters included on average 60% of patients, ranging from 48% (ADNI) to 71% (ADC), and the non-
memory clusters included on average 40% of patients, ranging from 29% (ADC) to 52% (ADNI). 
 
3.3 Cluster characterisation 
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We analysed cluster characteristics in terms of demographical, clinical and neurobiological 
characteristics. Associations for each cohort are shown in table 2. In the ADC, patients in the non-
memory cluster were younger, had lower MMSE scores, and had more severe atrophy of the posterior 
cortex. In the ADNI cohort, non-memory patients tended to be younger and less often APOE e4 
positive with relative hippocampal sparing, but these differences did not reach significance. In the 
DCN cohort, patients in the non-memory cluster had more severe atrophy of the posterior cortex. In 
the UCSF cohort, the non-memory cluster had lower MMSE scores, and patients were less often 
APOE e4 positive. There were no differences in WMH (ADC, ADNI, DCN). When we analysed 
pooled data, we found that across cohorts, patients in non-memory clusters were younger, less 
educated, reported shorter disease duration, had lower MMSE scores, were less often APOE e4 
positive, had less severe hippocampal atrophy, and more severe atrophy of the posterior cortex than 
patients in memory clusters. 
 
3.4 Validation of cognitive clusters after stratification for disease severity 
We tested whether disease severity influenced the cluster solutions by repeating NMF analyses in each 
cohort after stratifying for disease severity according to cohort median MMSE value. Results appeared 
to be robust across severity subgroups, with a memory cluster and non-memory cluster appearing in 
both the mild and the moderately demented patient strata (supplementary figures 1-4). Cluster 
characteristics in terms of demographic and neurobiological characteristics remained largely the same 
(supplementary tables 2 and 3). Differences between the memory and non-memory clusters were most 
pronounced in the mildly demented stratum.  
 
3.5 Validation of cognitive clusters in AD biomarker confirmed patients  
Availability of AD biomarkers is given in table 1 and 2. Based on χ2 analyses, no differences were 
found between the memory and non-memory clusters in terms of AD biomarker positivity (p > 0.05). 
Only for the ADC, enough data were available to repeat data-driven NMF analyses in AD biomarker 
confirmed patients (n=357 with CSF total tau/amyloid ß1-42 > 0.52[38]). Results appeared to be 
consistent with findings of the total cohorts, with a memory component mainly including RAVLT 
immediate and delayed recall, and a non-memory component mainly including TMT-A, TMT-B, 
fragmented letters, and letter digit substitution test (LDST), shown in supplementary figure 5. The 
memory cluster included 73% of patients, and the non-memory cluster 27% (supplementary figure 6). 
Consistent with characteristics of the total ADC, the non-memory cluster of the biomarker confirmed 
subset was younger (64 ± 8 versus 67 ± 8 years old, p < 0.01), had lower MMSE scores (20.9 ± 3.1 
versus 22.7 ± 3.0, p < 0.001), and had more severe posterior atrophy (1.51 ± 0.82 versus 1.13 ± 0.71, p 
< 0.05, rated according to a visual rating scale in which higher scores reflect more severe atrophy [29]) 
than the memory cluster. In addition, the non-memory cluster was less often APOE e4 positive than 
the memory cluster (61% versus 74%, p < 0.05). Results are provided in supplementary table 4. 
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4. DISCUSSION 
 
Across four independent AD dementia cohorts, we robustly found two cognitive clusters using a data-
driven dual-clustering approach. One cluster was characterized by more prominent memory 
impairment, and one cluster by more prominent impairment on non-memory tests. These memory and 
non-memory AD phenotypes were consistently found across cohorts, even though these cohorts 
differed in their patient populations (e.g. age, disease severity, mono-centre versus multi-centre, 
geographic location) and composition and extensiveness of neuropsychological test battery. Moreover, 
the clusters were associated with specific demographic, clinical, and neurobiological characteristics. 
These findings demonstrate the biological relevance of clinical heterogeneity in AD, as this may 
reflect variation in underlying disease mechanisms. 
 
Of all included patients, 40% belonged to a non-memory cluster. Compared to the memory clusters, 
non-memory cluster patients were younger, less educated, more often APOE e4 negative, had more 
severe posterior atrophy and relatively spared hippocampi. In addition, patients assigned to the non-
memory clusters reported shorter disease duration, but they had on average lower MMSE scores. 
Possibly, non-memory clusters are associated with a more aggressive disease progression.[41,42] 
Future studies should address the question whether cognitive subtypes are related to rate of decline, 
and hence suitable as putative prognostic marker. 
 
Among the suggested disease mechanisms causing heterogeneity, is the influence of copathologies, 
e.g. vascular pathology. We did not find differences in severity of ischemic vascular pathology 
(WMH) however. Of note, cognitive heterogeneity is most prominent in early onset AD patients, 
where AD pathology is often pure, and copathologies are less present.[43] Biomarker support for AD 
pathology was not available for each patient, but the available data showed no difference in AD 
biomarker positivity between clusters, suggesting that misdiagnosis is not a major driver of our 
findings. Variation in disease mechanisms could also be sought in the origin and spreading of 
neurofibrillary tangles (typically characterized by origin in the entorhinal cortex, progressing through 
the hippocampus to the association cortex, and finally to the cortex [44]) since the medial temporal 
lobe was relatively spared and the posterior cortex most prominently affected in the non-memory 
phenotype. This idea fits with the hypothesis that early-onset, APOE e4 negative AD patients are 
predisposed to vulnerability of cerebral networks beyond the medial temporal lobe.[44,45] This 
hypothesis coincides with an autopsy study that identified an AD subtype with relative less tangles in 
the hippocampus that was associated with younger age at death, male sex, rapid disease progression, 
and more often focal cortical clinical syndromes.[46] However, this phenotype only tended to have 
less often an APOE e4 positive genotype (p=0.067). Probably, the APOE e4 allele is not the only AD 
risk factor that modifies clinical heterogeneity; the effect of genetic risk factors on clinical AD 
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phenotype is still poorly understood. An increasing number of promising genes however are 
discovered to be associated with higher or reduced risks for developing AD and with certain 
neuropathological pathways.[47]  
 
A limitation of our study is that we did not have post mortem pathological confirmation of patients, so 
we cannot rule out the possibility of misdiagnosis. We think however that misdiagnoses will not have 
driven our results, as in all cohorts diagnoses were made according to careful application of clinical 
criteria, and repeating analyses in the CSF biomarker confirmed subset of ADC gave similar results.  
Furthermore, the present study could be biased since we excluded patients that were already severely 
demented (i.e. MMSE < 17) at diagnosis. We think that this selection bias could have resulted in 
underrepresentation of the non-memory phenotype, because atypical AD variants are less easily 
recognized as AD (especially at younger age, when other causes for cognitive complaints such as 
depression or burn-out are more common) and therefore probably more often associated with patients’ 
and doctors’ delay, and delay because of initial misdiagnoses. In addition, non-memory patients 
reporter shorter disease duration, while MMSE scores were already lower, possibly due to faster 
disease progression before diagnosis, suggesting higher risk for more severe dementia at time of 
diagnosis.  
It could be argued that the substantial differences between cohorts in patient population (e.g. 
geographically, age, disease severity, degree of cognitive heterogeneity within cohorts), and in 
extensiveness of neuropsychological test battery could be a limitation. However, we see this as a 
strong point of our study since we were able to replicate our finding of two robust clusters with their 
corresponding clinical characterisation. This suggests that the clusters we identified are generalizable 
to other AD populations; an often-encountered limitation of data driven methods to cluster patients is 
that of limited generalizability.  
 
Non-memory cluster patients had on average lower MMSE scores, and therefore we performed 
additional analyses to study whether clustering has been driven by disease severity. Repeating the 
clustering after stratification based on MMSE scores, a memory and a non-memory cluster were 
identified in each stratified cohort as well. Cluster differences in terms of clinical characteristics were 
largely similar for the strata, albeit more pronounced in the mildly demented stratum. This suggests 
that clinical heterogeneity is more prominently present in early stages of AD. 
 
Our results emphasize the presence of non-memory phenotypes in AD. Being able to identify AD 
subtypes is important in a clinical setting for early and adequate diagnosis and personalized medicine. 
Also, cognitive profiling should be taken into account when including patients for clinical trials, or 
when choosing cognitive outcomes to analyse the effect of an intervention. Furthermore, the existence 
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of these clusters, with similar patient characteristics across independent cohorts suggests that cognitive 
heterogeneity is caused by different disease mechanisms.  
 
In conclusion, we found two robust AD subtypes using a data-driven clustering approach in four AD 
cohorts. Identified clusters were associated with distinct demographical, clinical, and neurobiological 
characteristics, emphasizing the presence of cognitive heterogeneity in AD, and suggesting variation 
in underlying pathology.
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Table 1 Demographical and neurobiological characteristics of study cohorts 
 
ADC 
n = 496 
ADNI 
n = 376 
DCN 
n = 521 
UCSF 
n = 589 
Pooled sample 
n = 1.982 
Demographics      
   Age (yr) 67 ± 8 75 ± 8 72 ± 8 71 ± 10 71 ± 9 
   Female 258 (52%) 165 (44%) 313 (60%) 328 (56%) 1064 (54%) 
   Education* 5 (4-6) 16 (13-18) 11 (10-13) 16 (14-18) 0.00 ± 1.00 
   Duration complaints (yr) 2 (2-4) - 2 (1-3) - 2 (1-4) 
Global cognition      
   MMSE 22 ± 3 23 ± 2 23 ± 3 24 ± 4 23 ± 3 
APOE e4 genotype      
   APOE e4 positive  299 (67%) 128 (65%) 255 (64%) 100 (57%) 782 (64%) 
AD biomarkers †       
   AD biomarker available 389 (79%) 102 (27%) 193 (37%) 53 (9%) 737 (37%) 
   AD biomarker positive 358 (92%) 80 (78%) 164 (85%) 52 (98%) 654 (89%) 
MRI      
   Hippocampus‡ 1.5 (1-2) 2882 ± 511 2933 ± 473 - 0.00 ± 1.00  
   Posterior cortex§ 1 (1-2) - 1 (0-2) - 0.00 ± 1.00 
   WMH 1 (0-2) 0.41 (0.16-1.25) 0.5 (0-1) - 0.02 ± 1.01 
Data are presented in mean ± standard deviation, number (%), or median (2nd-4th quantile). Abbreviations: ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, APOE = Apolipoprotein E, c.o. = cut-off, CSF = cerebrospinal fluid, DCN = German Dementia Competence Network, MMSE = Mini-Mental State 
Examination, UCSF = University of California – San Francisco, WMH = white matter hyperintensities. *Education is given according to the Verhage scale (1-7 resp. low-high 
education[21]) for ADC, years of education for ADNI, DCN, and UCSF, and normalized scores for the pooled sample. †AD biomarkers are available as cerebrospinal fluid total 
tau/amyloid β1-42 (abnormal when > 0.52 according to Duits e.a. [38]) in the ADC ADNI, and DCN cohorts, or as Pittsburgh compound B positron emission tomography positivity in 
the UCSF cohort. ‡Hippocampal atrophy is measured according to the medial temporal lobe (MTA) visual rating scale for the ADC (0-4, higher scores reflect more severe atrophy 
[28]), and hippocampal volumes in mm3 for ADNI and DCN, and z-scores (in which normalized MTA scores are inverted) for the pooled sample. §Posterior atrophy is scored using 
a visual rating scale for the ADC [29] and the DCN, inverted z-scores are given for the pooled sample. WMH are scored according to a visual rating scale for the ADC [30] and the 
DCN (0-3, higher scores reflect more sever pathology), WMH volumes for ADNI [33], and z-scores are given for the pooled sample.  
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Table 2 Demographical and neurobiological cluster characteristics  
 ADC ADNI DCN UCSF Pooled sample 
 
mem 
n = 352 
(71%) 
non-mem 
n =144 
(29%) 
mem 
n = 182 
(48%) 
non-mem 
n = 194 
(52%) 
mem 
n = 335 
(64%) 
non-mem 
n = 186 
(36%) 
mem 
n = 326 
(55%) 
non-mem 
n = 263 
(45%) 
mem  
n = 1195 
(60%) 
non-mem  
n = 787 
(40%) 
Demographics           
   Age (years) 67.7  7.8 64.7  8.4* 76.2 ± 7.2 74.1 ± 8.3 72.3 ± 7.8 71.1 ± 9.0 72.1 ± 9.7 70.3 ± 11.0 71.5  8.7 70.4  9.9‡ 
   Female 180 (51%) 78 (54%) 78 (43%) 87 (45%) 201 (60%) 112 (60%) 171 (52%) 157 (60%) 630 (53%) 434 (55%) 
   Education 0.03  1.00 -0.06  1.01 0.01 ± 0.97 -0.01 ± 1.03  0.03 ± 1.00 -0.05 ± 1.00 0.1  1.00 -0.13  0.99 0.04  0.99 -0.07  1.01‡ 
   Duration complaints  3.1 ± 2.2 2.7 ± 1.7 - - 2.7 ± 2.3 2.4 ± 1.8 - - 2.9  2.3 2.5  1.8‡ 
Global cognition           
   MMSE 22.6  3.0 21.5  3.2† 23.5 ± 1.9 23.0 ± 2.3 23.4 ± 2.6 22.9 ± 3.0 24.4 ± 3.1 22.7  3.8* 23.5  2.8 22.6  3.2* 
APOE ε4 genotype           
   APOE ε4 positive  225 (70%) 74 (59%) 72 (67%) 56 (63%) 175 (67%) 80 (58%) 61 (66%) 39 (48%)‡ 533 (68%) 249 (58%)* 
AD biomarkers            
   AD biomarker available 275 (78%) 114 (79%) 52 (29%) 50 (26%) 123 (38%) 70 (38%) 25 (8%) 28 (11%) 475 (40%) 262 (33%) 
   AD biomarker positive 253 (92%) 105 (92%) 40 (77%) 40 (80%) 106 (86%) 58 (83%) 24 (96%) 28 (100%) 423 (89%) 231 (88%) 
MRI            
   Hippocampus  -0.07  1.00 0.18  0.97 -0.05 ± 1.01 0.05 ± 1.00 -0.09 ± 0.95 0.17 ± 1.07 - - -0.07 ± 1.00 0.12 ± 1.00† 
   Posterior cortex 0.11  0.94 -0.29  1.10† - - 0.08 ± 0.98 -0.15 ± 1.03‡ - - 0.09  0.96 -0.21  1.06* 
   WMH 0.10 ± -0.01 -0.07 ± -0.01 0.01 ± -0.32 -0.01 ± 0.95 -0.04 ± 0.96 0.07 ± 1.07 - - 0.03 ± -0.01 0.00 ± 1.05 
Data are presented in number (%) or mean ± standard deviation, also when not-normally distributed enabling clearer comparison between clusters. p-values are based on t-tests, χ2, or Kruskal Wallis analyses when 
appropriate. Normalized values are given for education, and MRI characteristics. AD biomarkers are available as cerebrospinal fluid total tau/amyloid β1-42 (abnormal when > 0.52 according to Duits e.a. [38]) in the 
ADC ADNI, and DCN cohorts, or as Pittsburgh compound B positron emission tomography positivity in the UCSF cohort. When MRI atrophy characteristics were measured using a visual rating scale in which a higher 
score reflects more severe atrophy, results were inverted so that higher scores reflect less atrophy. Differences between memory and non-memory clusters are shown in bold and indicated as follows: *p ≤ 0.001, †p ≤ 
0.01, ‡p ≤ 0.05. Interpretation: The non-memory clusters were younger (pooled sample, ADC), less educated (pooled sample), had shorter duration of complaints (pooled sample), lower MMSE scores (ADC, UCSF, 
pooled sample), were more often APOE e4 negative (UCSF, pooled sample), had less hippocampal atrophy (pooled sample), but more severe atrophy of the posterior cortex (ADC, DCN, pooled sample) than the 
memory clusters.  
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FIGURE LEGENDS 
 
 
Figure 1. Nonnegative Matrix Factorization is a dual-clustering approach, meaning that clustering includes two parallel steps. Firstly, neuropsychological (NP) test results are grouped together into neuropsychological 
profiles (‘components’), illustrated in the upper half of the figure, in which each row represents one neuropsychological test, and each column an identified neuropsychological component. The warmer the colour, the 
higher the test loads to the component when test scores are high (relatively spared cognition); the colder the colour, the lower the test loads to the component when test scores are high (relatively impaired cognition). 
The optimal number of components is based on the cophenetic correlation coefficient (for this example n=2). Secondly, patients are grouped together (into ‘clusters’) based on the fit of their neuropsychological profile 
to the identified neuropsychological component, taking each test’s load to the component into account. This step is illustrated in the lower half of the figure, in which each row represents one patient. The warmer the 
colour, the better the fit of patients’ neuropsychological profile to the neuropsychological profile of the identified component.  
 
Figure 2. Memory tests are indicated in dark blue. Abbreviations: ABCD = Arizona Battery for Communication Disorders of Dementia, ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, comp questions = comparative questions, CVLT = California Verbal Learning Test, DCN = German Dementia Competence Network, DS = Digit Span, FAB = Frontal Assessment Battery, 
LDST = Letter Digit Substitution Test, LM = CERAD Logical Memory, mem = memory-impaired, non-mem = memory-spared, NMF = Nonnegative Matrix Factorization, RAVLT = Rey Auditory Verbal Learning 
Test, TMT = Trail Making Test, UCSF = University of California – San Francisco, VAT = Visual Association Test, WL = CERAD Word List. In all cohorts, the optimal number of test clusters was two. In this figure, 
each row represents one neuropsychological test. The two columns represent the two found neuropsychological components. The warmer the colour, the higher the test loads to the component when test scores are high 
(relatively spared cognition); the colder the colour, the lower the test loads to the component when test scores are high (relatively impaired cognition). Interpretation: In each cohort, one component is associated with 
relative impairment of memory tests, therefore called the memory component. The other component is associated with relative impairment of non-memory functions, therefore called the non-memory component.   
 
Figure 3. Abbreviations: ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s disease Neuroimaging Initiative, DCN = German Dementia Competence Network, UCSF = University of California – San 
Francisco. Patients were assigned to either the memory or non-memory cluster based on the fit of their neuropsychological profile to the memory or non-memory component (figure 2). Each column represents one 
patient. The warmer the colour, the better the fit of patients’ neuropsychological profile to the neuropsychological profile of that component.  
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ABSTRACT 
Introduction Patients with Alzheimer’s disease (AD) show heterogeneity in profile of cognitive 
impairment. We aimed to identify cognitive subtypes in four large AD cohorts using a data-driven 
clustering approach.  
Methods We included probable AD dementia patients from the Amsterdam Dementia Cohort (ADC, 
n=496), Alzheimer’s Disease Neuroimaging Initiative (ADNI, n=376), German Dementia Competence 
Network (DCN, n=521), and University of California, San Francisco (UCSF, n=589). 
Neuropsychological data were clustered using Nonnegative Matrix Factorization. We explored clinical 
and neurobiological characteristics of identified clusters. 
Results In each cohort, a two-clusters solution best fitted the data (cophenetic correlation >.9): One 
cluster was memory-impaired, and the other relatively memory-spared. Pooled analyses showed that 
the memory-spared clusters (29-52% of patients) were younger, more often APOE e4 negative, and 
had more severe posterior atrophy compared to the memory-impaired clusters (all p<.05). 
Conclusions We could identify two robust cognitive clusters in four, independent large cohorts with 
distinct clinical characteristics.  
 
ABBREVIATIONS ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, APOE = Apolipoprotein E, CSF = cerebrospinal fluid, DCN = German 
Dementia Competence Network, MMSE = Mini-Mental State Examination, MRI = magnetic 
resonance imaging, MTA = medial temporal lobe atrophy, NMF = nonnegative matrix factorization, 
PA = atrophy of the posterior cortex, UCSF = University of California, San Francisco. 
 
HIGHLIGHTS (max 85 characters including spaces per point) 
 Alzheimer’s disease (AD) is a heterogeneous disorder (54) 
 We identified two cognitive AD subtypes in four cohorts with a data-driven approach (82) 
 Non-amnestic AD is associated with distinct neurobiological characteristics (77) 
 
RESEARCH IN CONTEXT  
1.Systematic review: Alzheimer’s disease (AD) is characterized by cognitive heterogeneity. We 
searched PubMed for clinical and neurobiological heterogeneity in AD profiles, and for data-driven 
approaches used to identify AD subtypes based on neuropsychological test scores. Several studies 
demonstrated the potential of clustering methods to identify cognitive AD subtypes. Identified 
subtypes showed distinct clinical characteristics. However none of the previous studies tested the 
generalizability of the cluster solutions, since those results were based on single-cohort studies. 
2. Interpretation: In four large AD cohorts, we consistently identified two cognitive clusters using 
Nonnegative Matrix Factorization of neuropsychological test scores. In each cohort one cluster most 
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prominently showed memory-impairment, and the other cluster was relatively memory-spared. These 
clusters were associated with distinct clinical characteristics. 
3. Future directions: Future research should aim to further study the underlying biological disease 
mechanisms that cause a non-memory AD phenotype.  
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1. Introduction 
 
Alzheimer’s disease (AD) dementia is characterized by progressive cognitive impairment in multiple 
cognitive domains, e.g. memory, language, visuospatial and executive functioning, and attention. 
Typically, AD is characterized by early and prominent memory loss.[1] A minority of patients has a 
prominent and relatively focal cognitive presentation, such as logopenic-variant primary progressive 
aphasia (lvPPA), posterior cortical atrophy (PCA), or a behavioural/dysexecutive subtype.[2-5] 
Atypical variants have been associated with specific demographic, genetic, and 
neuroimaging/biomarker findings that are distinct from those of typical amnestic patients (e.g. age at 
onset, apolipoprotein E [APOE] genotype, distribution of cortical atrophy, hypometabolism, tau 
deposition, cerebrospinal fluid biomarker concentrations, and pathological findings).[6-10] However, 
even patients who do not display a defined subtype also show considerable variation in patterns of 
cognitive impairment. Earlier studies demonstrated the potential to capture cognitive heterogeneity in 
AD using a data-driven clustering approach.[11-14] Studies differed in sample size, clinical diagnosis 
of included patients, available neuropsychological test results, available neurobiological characteristics 
to compare clusters with, and clustering technique. This has resulted in different numbers of clusters, 
with different cognitive and neurobiological characteristics. Although those studies were clearly 
suggestive of variability in underlying pathological mechanisms, it is difficult to generalise the 
findings, since they result from single studies that show considerable variability in patient population 
and methodological approaches. 
 
In the present study, we aimed to identify cognitive subtypes and to study whether these subtypes 
could be replicated in three independent AD dementia cohorts. For the identification of cognitive AD 
subtypes, we used Nonnegative Matrix Factorization (NMF).[15-18] Based on earlier descriptions of 
cognitive heterogeneity, we expected NMF to identify at least a cluster including patients with typical 
amnestic AD, and one or more other clusters including patients with non-amnestic features.[15-18]  
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2. Methods 
 
2.1. Patients 
We selected AD patients from four large cohorts: The Amsterdam Dementia Cohort (ADC), the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI), the German Dementia Competence Network 
(DCN), and the University of California, San Francisco Memory and Aging Center research cohort 
(UCSF). Patients were selected based on 1) clinical diagnosis of probable AD dementia, 2) availability 
of neuropsychological test results, and 3) Mini-Mental State Examination (MMSE) score >16/30.[19] 
In the ADC and UCSF cohort, patients with focal presentations lvPPA, PCA, and the 
behavioural/dysexecutive subtype of probable AD dementia were included, while such subjects were 
explicitly excluded from participation in the ADNI and DCN studies.  
 
From the ADC we selected 496 patients with probable AD.[20] Patients visited the outpatient memory 
clinic of the VU University Alzheimer Center between 2008 and 2013. Standard dementia screening 
included for most patients medical history and medication use, physical and neurological examination, 
extensive neuropsychological evaluation, screening laboratory tests, APOE genotyping, magnetic 
resonance imaging (MRI), and lumbar puncture (LP). In the ADC, level of education was defined 
according to a rating scale ranging from 1 (low, primary school not finished) to 7 (high, university 
degree).[21] All participants provided written informed consent to use their clinical data for research 
purposes. The local ethical committee approved the study. 
 
From the ADNI database (adni.loni.usc.edu) we selected 376 probable AD patients. Patients were 
recruited in over 50 sites across the U.S. and Canada (www.adni-info.org). Standard workup included 
medical history, physical and neurological examination, extensive neuropsychological evaluation, 
screening laboratory tests, APOE genotyping, neuroimaging including MRI, and LP. For the present 
study, we used data of screening and baseline visits, acquired for ADNI-1 or ADNI-2 between 2005 
and 2013. All patients gave written informed consent at screening.  
 
From the DCN cohort database (http://www.kompetenznetz-demenzen.de) we selected 521 probable 
AD patients.[22] The DCN is a collaboration of fourteen specialized German memory clinics from 
university hospitals. All patients were offered a uniform dementia screening at first visit between 2003 
and 2007, including medical history, physical and neurological examination, extensive 
neuropsychological evaluation, screening laboratory tests, MRI scan, and LP. The DCN study protocol 
was approved by the Institutional Review Boards of all participating study centres.[22] All patients, or 
their legal guardians, provided written informed consent. 
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From the UCSF research cohort we selected 589 probable AD patients.[23] Patients were either seen 
in the outpatient memory clinic, or for a research assessment in the UCSF Alzheimer’s Disease 
Research Center. All patients were assessed at first visit between 1998 and 2013. Standardized 
dementia screening included medical history, physical and neurological examination, 
neuropsychological evaluation, screening laboratory tests, APOE genotyping, and neuroimaging 
including MRI. A core screening neuropsychological battery was performed in both the clinical and 
research settings. All patient and informants provided written informed consent. Surrogate consent 
was accepted when patients lacked capacity to provide consent themselves. The local medical ethical 
committee approved the study. 
 
2.2 Neuropsychological tests 
Neuropsychological data included tests covering the major cognitive domains in each cohort, but the 
exact composition of neuropsychological test batteries differed across cohorts. Neuropsychological 
tests included for analysis in this study are shown in supplementary table 1. The number of missing 
neuropsychological values differed across cohorts and within neuropsychological test batteries (on 
average 20% in ADC, 27% in ADNI, 1% in DCN, 12% in UCSF). Main reasons for missingness are 
practical reasons unrelated to the data (random). In part of the cases however, tests could not be 
finished due to cognitive impairment, whereas scoring differed across cohorts and between tests (i.e. 
assignment of missing value or minimum score). The clustering technique NMF does not allow for 
missing data or negative values. In order to reduce selection bias, we did not select patients based on 
completeness of datasets, but we completed the datasets using a multiple imputation approach that is 
commonly used as a reliable method to estimate missing data. 
We imputed missing neuropsychological data using R package Multivariate Imputation by Chained 
Equations (MICE, version 2.25).[24,25] MICE estimates missing neuropsychological values by 
predicting these values from the relationships with other neuropsychological variables. We also 
included predictors age, gender, MMSE, and when available education, duration of complaints, 
Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-cog) or Cambridge Cognitive 
Examination (CAMCOG) or Cognitive Dementia Rating (CDR) sum of boxes in the imputation 
model. We ran MICE 50 times per cohort, resulting in 50 imputed datasets for each cohort. For further 
analyses, we included pooled measures over the 50 derived imputed datasets per cohort.[26,27] We 
inverted values when appropriate, so that for all tests lower scores reflect worse cognitive impairment. 
Next, the imputed neuropsychological data were normalized and scaled to include only positive values 
(0-1). 
 
2.3 MRI characteristics 
MRI characteristics were available for patients from the ADC, ADNI, and DCN cohorts.  
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For the ADC cohort, imaging data was obtained on a 1.5T or 3T scan. Visual ratings of medial 
temporal lobe atrophy (MTA; range 0-4[28]), posterior atrophy (PA; range 0-3[29]), and white matter 
hyperintensities (WMH; range 0-3[30]) were performed by an experienced neuroradiologist. For 
ADNI, a structural MRI 1.5T scan was performed on screening or baseline visit.[31] Image processing 
has been done with cortical reconstruction and volumetric segmentations using FreeSurfer 4.3 
(surfer.nmr.mgh.harvard.edu/).[32] Hippocampal and WMH volumes were downloaded from the 
ADNI website (ida.loni.usc.edu/).[33] For the DCN cohort, MRI data was obtained from multiple 1.5T 
scanners with standardized MRI acquisition guidelines across centres.[22,34] PA and WMH were 
scored by experienced neuroradiologists using a visual rating scale in which higher scores reflect more 
severe abnormalities (range 0-3). Furthermore, hippocampal volumes were measured using FMRIB’s 
Integrated Registration and Segmentation Tool (FIRST) from the FMRIB Software Library (FSL) 
package of tools.[35,36] For all atrophy measurements, we included the mean of left and right 
hemisphere.  
 
2.4 APOE e4 genotype 
APOE e4 genotype was available in the ADC (n=448; 90%), ADNI (n=196; 52%), DCN (n=397; 
76%), and UCSF (n=175; 30%) cohorts. We dichotomised APOE e4 genotype according to the 
presence or absence of one or more APOE e4 alleles. APOE genotype was assessed using the Light 
Cycler APOE mutation detection method (Roche Diagnostics GmbH, Mannheim, Germany) in the 
ADC. For ADNI, APOE alleles were genotyped using DNA extracted by Cogenics. For the DCN, 
APOE genotype was assessed using Qiagen blood isolation kit (Qiagen, Hilden, Germany). For UCSF, 
APOE genotype was conducted using a TaqMan Allelic Discrimination Assay on an ABI 7900HT 
Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). 
 
2.5 AD biomarkers 
Cerebrospinal fluid (CSF) markers amyloid-beta1-42 (Abeta1-42), and total tau (tau) were available for 
ADC (n=389; 79%), ADNI (n=102; 27%), and DCN (n=193; 37%). CSF biomarkers were assessed 
using Sandwich ELISAs (Fujirebio, Gent, Belgium) in ADC and DCN[37], and Multiplex xMAP 
Luminex platform (Luminex Corp, Austin, TX) with Fujirebio immunoassay kit–based reagents 
(INNO-BIA Alzbio3; Fujirebio, Ghent, Belgium) in ADNI. CSF biomarkers were considered positive 
for AD when tau / Abeta1-42 ratio was > 0.52 [38]. Pittsburgh compound B position emission 
tomography visual reading results (i.e. positive or negative) were available for the UCSF cohort 
(n=52; 9%).  
 
2.6 Statistical analysis 
For statistical analyses, we used RStudio for Mac version 3.2.2 (Integrated Development for R. 
RStudio, Inc., Boston, MA, http://www.rstudio.com). Clustering was performed with the R package 
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Nonnegative Matrix Factorization (NMF, version 0.20.6).[39] Clustering is a data-driven method to 
divide a heterogeneous set of objects (patients) in subgroups that are more homogeneous in terms of 
characteristics provided as input for the clustering (neuropsychological test results). NMF is a dual-
clustering approach, meaning that clustering includes two parallel steps (illustrated in figure 1). 
Firstly, neuropsychological test results are grouped together into neuropsychological profiles 
(‘components’), and neuropsychological tests that determine these components can be identified by 
their component loading. Secondly, patients are grouped together based on the fit of their 
neuropsychological profile to the neuropsychological summary component. The optimal number of 
clusters is based on the most consistent assignment of patients to the identified cognitive profiles in 
the multiple runs of NMF. The stability of the cluster solution is assessed with the cophenetic 
correlation coefficient, that measures how consistently tests and subjects are assigned to a given 
component, ranging between 0 and 1 (i.e. no stability to stable cluster solution). For each cohort, we 
determined the optimal number of clusters based on the highest cophenetic correlation coefficient for 2 
to 9 cluster solutions.[15] We used the ‘nonsmooth’ NMF algorithm that introduces an intermediate 
smoothing matrix to enhance sparsity of the clusters.[40]  
Characterization of identified clusters in terms of neuropsychological profile was based on the most 
strongly loading neuropsychological tests.[17] For characterization of identified clusters in terms of 
demographic, clinical, and neurobiological characteristics, we analysed age, sex, education, disease 
duration reported by the patient, MMSE, APOE e4 genotype, CSF biomarkers, MRI atrophy, and 
WMH measurements using χ2, t-tests, or Kruskal Wallis tests where appropriate. These analyses were 
performed for each cohort separately. In addition, for each cluster we pooled the patient characteristics 
over the cohorts in order to compare them for the total sample. To this end we Z-transformed variables 
with different scales (i.e. education, CSF biomarkers, and MRI biomarkers) before pooling. When 
atrophy of the hippocampus and the posterior cortex was measured using a visual rating scale in which 
higher scores reflect more severe atrophy, the normalized scores were inverted so that higher scores 
reflect less atrophy in all cohorts and the pooled sample.
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3. RESULTS 
 
3.1 Cohort characteristics 
Characteristics of all cohorts are summarized in table 1. On average, patients were 719 years old, 
with the ADC being the youngest cohort. 54% of patients were female, ranging from 44% (ADNI) to 
60% (DCN). Patients were mildly-to moderately demented, with an average MMSE varying between 
cohorts from 22-24. Roughly two thirds of patients were APOE e4 carrier, ranging from 57% (UCSF) 
to 67% (ADC).  
 
3.2 NMF clusters of cognitive subtypes 
NMF is a dual-clustering approach; first, neuropsychological tests are grouped into components, and 
second patients are clustered based on the fit of their neuropsychological profiles to the profiles of the 
identified neuropsychological components, taking the load of each test to the component into account. 
NMF showed that within each cohort, the optimal number of clusters was two, as the solution with 
two clusters showed the strongest cophenetic correlation (>.90).  
 
Results of the clustering of tests are shown in figure 2. In the ADC, one neuropsychological 
component mainly included memory tests Rey auditory verbal learning test (RAVLT) immediate and 
delayed recall. The other component included mainly non-memory tests trail making test (TMT)-A 
and TMT-B, and fragmented letters. In the ADNI cohort, one neuropsychological component mainly 
included memory tests logical memory immediate and delayed recall, and RAVLT delayed recall. The 
other component mainly included non-memory tests TMT-A and TMT-B. In the DCN cohort, one 
neuropsychological component included mainly memory tests logical memory immediate and delayed 
recall, word list immediate and delayed recall of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD), and Rey figure recall. The other component included mainly non-
memory tests TMT-A, TMT-B, clock drawing, and CERAD figure copy. In the UCSF cohort, one 
neuropsychological component included mainly memory tests figure recall, and the California verbal 
learning test (CVLT) delayed recall. The other component included mainly non-memory tests 
modified trails, design fluency, and stroop interference.  
 
Patients were assigned to either of two clusters based on the fit of their neuropsychological test results 
to the memory or non-memory component in each cohort (figure 3). Across all cohorts, the memory 
clusters included on average 60% of patients, ranging from 48% (ADNI) to 71% (ADC), and the non-
memory clusters included on average 40% of patients, ranging from 29% (ADC) to 52% (ADNI). 
 
3.3 Cluster characterisation 
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We analysed cluster characteristics in terms of demographical, clinical and neurobiological 
characteristics. Associations for each cohort are shown in table 2. In the ADC, patients in the non-
memory cluster were younger, had lower MMSE scores, and had more severe atrophy of the posterior 
cortex. In the ADNI cohort, non-memory patients tended to be younger and less often APOE e4 
positive with relative hippocampal sparing, but these differences did not reach significance. In the 
DCN cohort, patients in the non-memory cluster had more severe atrophy of the posterior cortex. In 
the UCSF cohort, the non-memory cluster had lower MMSE scores, and patients were less often 
APOE e4 positive. There were no differences in WMH (ADC, ADNI, DCN). When we analysed 
pooled data, we found that across cohorts, patients in non-memory clusters were younger, less 
educated, reported shorter disease duration, had lower MMSE scores, were less often APOE e4 
positive, had less severe hippocampal atrophy, and more severe atrophy of the posterior cortex than 
patients in memory clusters. 
 
3.4 Validation of cognitive clusters after stratification for disease severity 
We tested whether disease severity influenced the cluster solutions by repeating NMF analyses in each 
cohort after stratifying for disease severity according to cohort median MMSE value. Results appeared 
to be robust across severity subgroups, with a memory cluster and non-memory cluster appearing in 
both the mild and the moderately demented patient strata (supplementary figures 1-4). Cluster 
characteristics in terms of demographic and neurobiological characteristics remained largely the same 
(supplementary tables 2 and 3). Differences between the memory and non-memory clusters were most 
pronounced in the mildly demented stratum.  
 
3.5 Validation of cognitive clusters in AD biomarker confirmed patients  
Availability of AD biomarkers is given in table 1 and 2. Based on χ2 analyses, no differences were 
found between the memory and non-memory clusters in terms of AD biomarker positivity (p > 0.05). 
Only for the ADC, enough data were available to repeat data-driven NMF analyses in AD biomarker 
confirmed patients (n=357 with CSF total tau/amyloid ß1-42 > 0.52[38]). Results appeared to be 
consistent with findings of the total cohorts, with a memory component mainly including RAVLT 
immediate and delayed recall, and a non-memory component mainly including TMT-A, TMT-B, 
fragmented letters, and letter digit substitution test (LDST), shown in supplementary figure 5. The 
memory cluster included 73% of patients, and the non-memory cluster 27% (supplementary figure 6). 
Consistent with characteristics of the total ADC, the non-memory cluster of the biomarker confirmed 
subset was younger (64 ± 8 versus 67 ± 8 years old, p < 0.01), had lower MMSE scores (20.9 ± 3.1 
versus 22.7 ± 3.0, p < 0.001), and had more severe posterior atrophy (1.51 ± 0.82 versus 1.13 ± 0.71, p 
< 0.05, rated according to a visual rating scale in which higher scores reflect more severe atrophy [29]) 
than the memory cluster. In addition, the non-memory cluster was less often APOE e4 positive than 
the memory cluster (61% versus 74%, p < 0.05). Results are provided in supplementary table 4. 
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4. DISCUSSION 
 
Across four independent AD dementia cohorts, we robustly found two cognitive clusters using a data-
driven dual-clustering approach. One cluster was characterized by more prominent memory 
impairment, and one cluster by more prominent impairment on non-memory tests. These memory and 
non-memory AD phenotypes were consistently found across cohorts, even though these cohorts 
differed in their patient populations (e.g. age, disease severity, mono-centre versus multi-centre, 
geographic location) and composition and extensiveness of neuropsychological test battery. Moreover, 
the clusters were associated with specific demographic, clinical, and neurobiological characteristics. 
These findings demonstrate the biological relevance of clinical heterogeneity in AD, as this may 
reflect variation in underlying disease mechanisms. 
 
Of all included patients, 40% belonged to a non-memory cluster. Compared to the memory clusters, 
non-memory cluster patients were younger, less educated, more often APOE e4 negative, had more 
severe posterior atrophy and relatively spared hippocampi. In addition, patients assigned to the non-
memory clusters reported shorter disease duration, but they had on average lower MMSE scores. 
Possibly, non-memory clusters are associated with a more aggressive disease progression.[41,42] 
Future studies should address the question whether cognitive subtypes are related to rate of decline, 
and hence suitable as putative prognostic marker. 
 
Among the suggested disease mechanisms causing heterogeneity, is the influence of copathologies, 
e.g. vascular pathology. We did not find differences in severity of ischemic vascular pathology 
(WMH) however. Of note, cognitive heterogeneity is most prominent in early onset AD patients, 
where AD pathology is often pure, and copathologies are less present.[43] Biomarker support for AD 
pathology was not available for each patient, but the available data showed no difference in AD 
biomarker positivity between clusters, suggesting that misdiagnosis is not a major driver of our 
findings. Variation in disease mechanisms could also be sought in the origin and spreading of 
neurofibrillary tangles (typically characterized by origin in the entorhinal cortex, progressing through 
the hippocampus to the association cortex, and finally to the cortex [44]) since the medial temporal 
lobe was relatively spared and the posterior cortex most prominently affected in the non-memory 
phenotype. This idea fits with the hypothesis that early-onset, APOE e4 negative AD patients are 
predisposed to vulnerability of cerebral networks beyond the medial temporal lobe.[44,45] This 
hypothesis coincides with an autopsy study that identified an AD subtype with relative less tangles in 
the hippocampus that was associated with younger age at death, male sex, rapid disease progression, 
and more often focal cortical clinical syndromes.[46] However, this phenotype only tended to have 
less often an APOE e4 positive genotype (p=0.067). Probably, the APOE e4 allele is not the only AD 
risk factor that modifies clinical heterogeneity; the effect of genetic risk factors on clinical AD 
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phenotype is still poorly understood. An increasing number of promising genes however are 
discovered to be associated with higher or reduced risks for developing AD and with certain 
neuropathological pathways.[47]  
 
A limitation of our study is that we did not have post mortem pathological confirmation of patients, so 
we cannot rule out the possibility of misdiagnosis. We think however that misdiagnoses will not have 
driven our results, as in all cohorts diagnoses were made according to careful application of clinical 
criteria, and repeating analyses in the CSF biomarker confirmed subset of ADC gave similar results.  
Furthermore, the present study could be biased since we excluded patients that were already severely 
demented (i.e. MMSE < 17) at diagnosis. We think that this selection bias could have resulted in 
underrepresentation of the non-memory phenotype, because atypical AD variants are less easily 
recognized as AD (especially at younger age, when other causes for cognitive complaints such as 
depression or burn-out are more common) and therefore probably more often associated with patients’ 
and doctors’ delay, and delay because of initial misdiagnoses. In addition, non-memory patients 
reporter shorter disease duration, while MMSE scores were already lower, possibly due to faster 
disease progression before diagnosis, suggesting higher risk for more severe dementia at time of 
diagnosis.  
It could be argued that the substantial differences between cohorts in patient population (e.g. 
geographically, age, disease severity, degree of cognitive heterogeneity within cohorts), and in 
extensiveness of neuropsychological test battery could be a limitation. However, we see this as a 
strong point of our study since we were able to replicate our finding of two robust clusters with their 
corresponding clinical characterisation. This suggests that the clusters we identified are generalizable 
to other AD populations; an often-encountered limitation of data driven methods to cluster patients is 
that of limited generalizability.  
 
Non-memory cluster patients had on average lower MMSE scores, and therefore we performed 
additional analyses to study whether clustering has been driven by disease severity. Repeating the 
clustering after stratification based on MMSE scores, a memory and a non-memory cluster were 
identified in each stratified cohort as well. Cluster differences in terms of clinical characteristics were 
largely similar for the strata, albeit more pronounced in the mildly demented stratum. This suggests 
that clinical heterogeneity is more prominently present in early stages of AD. 
 
Our results emphasize the presence of non-memory phenotypes in AD. Being able to identify AD 
subtypes is important in a clinical setting for early and adequate diagnosis and personalized medicine. 
Also, cognitive profiling should be taken into account when including patients for clinical trials, or 
when choosing cognitive outcomes to analyse the effect of an intervention. Furthermore, the existence 
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of these clusters, with similar patient characteristics across independent cohorts suggests that cognitive 
heterogeneity is caused by different disease mechanisms.  
 
In conclusion, we found two robust AD subtypes using a data-driven clustering approach in four AD 
cohorts. Identified clusters were associated with distinct demographical, clinical, and neurobiological 
characteristics, emphasizing the presence of cognitive heterogeneity in AD, and suggesting variation 
in underlying pathology.
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Table 1 Demographical and neurobiological characteristics of study cohorts 
 
ADC 
n = 496 
ADNI 
n = 376 
DCN 
n = 521 
UCSF 
n = 589 
Pooled sample 
n = 1.982 
Demographics      
   Age (yr) 67 ± 8 75 ± 8 72 ± 8 71 ± 10 71 ± 9 
   Female 258 (52%) 165 (44%) 313 (60%) 328 (56%) 1064 (54%) 
   Education* 5 (4-6) 16 (13-18) 11 (10-13) 16 (14-18) 0.00 ± 1.00 
   Duration complaints (yr) 2 (2-4) - 2 (1-3) - 2 (1-4) 
Global cognition      
   MMSE 22 ± 3 23 ± 2 23 ± 3 24 ± 4 23 ± 3 
APOE e4 genotype      
   APOE e4 positive  299 (67%) 128 (65%) 255 (64%) 100 (57%) 782 (64%) 
AD biomarkers †       
   AD biomarker available 389 (79%) 102 (27%) 193 (37%) 53 (9%) 737 (37%) 
   AD biomarker positive 358 (92%) 80 (78%) 164 (85%) 52 (98%) 654 (89%) 
MRI      
   Hippocampus‡ 1.5 (1-2) 2882 ± 511 2933 ± 473 - 0.00 ± 1.00  
   Posterior cortex§ 1 (1-2) - 1 (0-2) - 0.00 ± 1.00 
   WMH 1 (0-2) 0.41 (0.16-1.25) 0.5 (0-1) - 0.02 ± 1.01 
Data are presented in mean ± standard deviation, number (%), or median (2nd-4th quantile). Abbreviations: ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, APOE = Apolipoprotein E, c.o. = cut-off, CSF = cerebrospinal fluid, DCN = German Dementia Competence Network, MMSE = Mini-Mental State 
Examination, UCSF = University of California – San Francisco, WMH = white matter hyperintensities. *Education is given according to the Verhage scale (1-7 resp. low-high 
education[21]) for ADC, years of education for ADNI, DCN, and UCSF, and normalized scores for the pooled sample. †AD biomarkers are available as cerebrospinal fluid total 
tau/amyloid β1-42 (abnormal when > 0.52 according to Duits e.a. [38]) in the ADC ADNI, and DCN cohorts, or as Pittsburgh compound B positron emission tomography positivity in 
the UCSF cohort. ‡Hippocampal atrophy is measured according to the medial temporal lobe (MTA) visual rating scale for the ADC (0-4, higher scores reflect more severe atrophy 
[28]), and hippocampal volumes in mm3 for ADNI and DCN, and z-scores (in which normalized MTA scores are inverted) for the pooled sample. §Posterior atrophy is scored using 
a visual rating scale for the ADC [29] and the DCN, inverted z-scores are given for the pooled sample. WMH are scored according to a visual rating scale for the ADC [30] and the 
DCN (0-3, higher scores reflect more sever pathology), WMH volumes for ADNI [33], and z-scores are given for the pooled sample.  
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Table 2 Demographical and neurobiological cluster characteristics  
 ADC ADNI DCN UCSF Pooled sample 
 
mem 
n = 352 
(71%) 
non-mem 
n =144 
(29%) 
mem 
n = 182 
(48%) 
non-mem 
n = 194 
(52%) 
mem 
n = 335 
(64%) 
non-mem 
n = 186 
(36%) 
mem 
n = 326 
(55%) 
non-mem 
n = 263 
(45%) 
mem  
n = 1195 
(60%) 
non-mem  
n = 787 
(40%) 
Demographics           
   Age (years) 67.7  7.8 64.7  8.4* 76.2 ± 7.2 74.1 ± 8.3 72.3 ± 7.8 71.1 ± 9.0 72.1 ± 9.7 70.3 ± 11.0 71.5  8.7 70.4  9.9‡ 
   Female 180 (51%) 78 (54%) 78 (43%) 87 (45%) 201 (60%) 112 (60%) 171 (52%) 157 (60%) 630 (53%) 434 (55%) 
   Education 0.03  1.00 -0.06  1.01 0.01 ± 0.97 -0.01 ± 1.03  0.03 ± 1.00 -0.05 ± 1.00 0.1  1.00 -0.13  0.99 0.04  0.99 -0.07  1.01‡ 
   Duration complaints  3.1 ± 2.2 2.7 ± 1.7 - - 2.7 ± 2.3 2.4 ± 1.8 - - 2.9  2.3 2.5  1.8‡ 
Global cognition           
   MMSE 22.6  3.0 21.5  3.2† 23.5 ± 1.9 23.0 ± 2.3 23.4 ± 2.6 22.9 ± 3.0 24.4 ± 3.1 22.7  3.8* 23.5  2.8 22.6  3.2* 
APOE ε4 genotype           
   APOE ε4 positive  225 (70%) 74 (59%) 72 (67%) 56 (63%) 175 (67%) 80 (58%) 61 (66%) 39 (48%)‡ 533 (68%) 249 (58%)* 
AD biomarkers            
   AD biomarker available 275 (78%) 114 (79%) 52 (29%) 50 (26%) 123 (38%) 70 (38%) 25 (8%) 28 (11%) 475 (40%) 262 (33%) 
   AD biomarker positive 253 (92%) 105 (92%) 40 (77%) 40 (80%) 106 (86%) 58 (83%) 24 (96%) 28 (100%) 423 (89%) 231 (88%) 
MRI            
   Hippocampus  -0.07  1.00 0.18  0.97 -0.05 ± 1.01 0.05 ± 1.00 -0.09 ± 0.95 0.17 ± 1.07 - - -0.07 ± 1.00 0.12 ± 1.00† 
   Posterior cortex 0.11  0.94 -0.29  1.10† - - 0.08 ± 0.98 -0.15 ± 1.03‡ - - 0.09  0.96 -0.21  1.06* 
   WMH 0.10 ± -0.01 -0.07 ± -0.01 0.01 ± -0.32 -0.01 ± 0.95 -0.04 ± 0.96 0.07 ± 1.07 - - 0.03 ± -0.01 0.00 ± 1.05 
Data are presented in number (%) or mean ± standard deviation, also when not-normally distributed enabling clearer comparison between clusters. p-values are based on t-tests, χ2, or Kruskal Wallis analyses when 
appropriate. Normalized values are given for education, and MRI characteristics. AD biomarkers are available as cerebrospinal fluid total tau/amyloid β1-42 (abnormal when > 0.52 according to Duits e.a. [38]) in the 
ADC ADNI, and DCN cohorts, or as Pittsburgh compound B positron emission tomography positivity in the UCSF cohort. When MRI atrophy characteristics were measured using a visual rating scale in which a higher 
score reflects more severe atrophy, results were inverted so that higher scores reflect less atrophy. Differences between memory and non-memory clusters are shown in bold and indicated as follows: *p ≤ 0.001, †p ≤ 
0.01, ‡p ≤ 0.05. Interpretation: The non-memory clusters were younger (pooled sample, ADC), less educated (pooled sample), had shorter duration of complaints (pooled sample), lower MMSE scores (ADC, UCSF, 
pooled sample), were more often APOE e4 negative (UCSF, pooled sample), had less hippocampal atrophy (pooled sample), but more severe atrophy of the posterior cortex (ADC, DCN, pooled sample) than the 
memory clusters.  
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FIGURE LEGENDS 
 
 
Figure 1. Nonnegative Matrix Factorization is a dual-clustering approach, meaning that clustering includes two parallel steps. Firstly, neuropsychological (NP) test results are grouped together into neuropsychological 
profiles (‘components’), illustrated in the upper half of the figure, in which each row represents one neuropsychological test, and each column an identified neuropsychological component. The warmer the colour, the 
higher the test loads to the component when test scores are high (relatively spared cognition); the colder the colour, the lower the test loads to the component when test scores are high (relatively impaired cognition). 
The optimal number of components is based on the cophenetic correlation coefficient (for this example n=2). Secondly, patients are grouped together (into ‘clusters’) based on the fit of their neuropsychological profile 
to the identified neuropsychological component, taking each test’s load to the component into account. This step is illustrated in the lower half of the figure, in which each row represents one patient. The warmer the 
colour, the better the fit of patients’ neuropsychological profile to the neuropsychological profile of the identified component.  
 
Figure 2. Memory tests are indicated in dark blue. Abbreviations: ABCD = Arizona Battery for Communication Disorders of Dementia, ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s Disease 
Neuroimaging Initiative, comp questions = comparative questions, CVLT = California Verbal Learning Test, DCN = German Dementia Competence Network, DS = Digit Span, FAB = Frontal Assessment Battery, 
LDST = Letter Digit Substitution Test, LM = CERAD Logical Memory, mem = memory-impaired, non-mem = memory-spared, NMF = Nonnegative Matrix Factorization, RAVLT = Rey Auditory Verbal Learning 
Test, TMT = Trail Making Test, UCSF = University of California – San Francisco, VAT = Visual Association Test, WL = CERAD Word List. In all cohorts, the optimal number of test clusters was two. In this figure, 
each row represents one neuropsychological test. The two columns represent the two found neuropsychological components. The warmer the colour, the higher the test loads to the component when test scores are high 
(relatively spared cognition); the colder the colour, the lower the test loads to the component when test scores are high (relatively impaired cognition). Interpretation: In each cohort, one component is associated with 
relative impairment of memory tests, therefore called the memory component. The other component is associated with relative impairment of non-memory functions, therefore called the non-memory component.   
 
Figure 3. Abbreviations: ADC = Amsterdam Dementia Cohort, ADNI = Alzheimer’s disease Neuroimaging Initiative, DCN = German Dementia Competence Network, UCSF = University of California – San 
Francisco. Patients were assigned to either the memory or non-memory cluster based on the fit of their neuropsychological profile to the memory or non-memory component (figure 2). Each column represents one 
patient. The warmer the colour, the better the fit of patients’ neuropsychological profile to the neuropsychological profile of that component.  
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Revisions cognitive AD clusters robustly identified in four cohorts 19/01/2017  
We thank the reviewers for their careful reading and thoughtful comments. We have revised the 
manuscript according to their suggestions and feel that the paper has improved considerably. Please find 
below our response in which we describe how we dealt with each comment in a point-by-point fashion. 
Changes made to the manuscript have been written in blue.  
 
 
REVIEWER #1 
 
This is a very well written manuscript that looks at clustering groups of AD patients according to their 
clustered performance on neuropsychological tasks. Although I am unfamiliar with this statistical 
technique, I could understand the method as described in the manuscript. The authors then compared the 
memory and non-memory clusters of patients to determine their differences. Broadly, the non-memory 
group tended to be younger, non-APOE4 carriers and showed posterior atrophy. 
 
1. I only have one comment, and this is more a musing that I wonder if the authors have thought 
about: investigations of AD populations are difficult due to the issue of survivor bias (both in 
terms of the AD patients that are left to study, and the AD patients that are too unwell to be 
studied). While this is a large grouping of participants across many studies, I still always wonder 
about what inevitable bias we cannot avoid. For instance, is it the fact that there are more APOE4 
carriers in the memory group, because of some curiosity to do with the non-memory group rather 
than a "real" biological distinction between groups of AD patients? Again, this is not something 
that can adequately be addressed here, but something that is often worried about by 
epidemiologists and I am curious to know whether the authors have thought about this. 
 
We thank the editor for his/her friendly words and for the interesting consideration. Indeed, it is 
very important to consider possible sources of bias. We excluded patients with MMSE < 17/30 to 
limit the influences of floor effects on neuropsychological tests that were used for clustering, and 
because cognitive heterogeneity is most prominently recognizable in the early stages. Please note 
that we included data of patients who received a diagnosis of probable AD at their’ first visits, 
therefore data of earlier stages were not available. We think that patients’ and doctors’ delay is 
probably shorter in the more typical (well-known) memory AD than in the less typical non-
memory AD, as the latter is probably less well recognized in early stages and more often 
misdiagnosed (e.g. as burn-out, depression). We therefore think that – if anything - this selection 
bias probably underestimated the presence of non-memory AD phenotype in our study. Suggested 
underestimation of the non-memory phenotype is strengthened by the finding that non-memory 
patients reported shorter disease duration, while MMSE scores were already lower at first visit, 
suggesting faster disease progression before diagnosis and higher risk for more severe dementia 
at time of diagnosis. We added considerations regarding bias in the discussion (page 12).  
 
 
 
*Response to Reviewers
Revisions cognitive AD clusters robustly identified in four cohorts 19/01/2017  
REVIEWER #2 
 
This is a paper on clusters of cognitive profiles in AD. The authors report that there are two clusters in 
patients with a clinical diagnosis of AD dementia, one with predominance of memory impairment and one 
with predominance of impairment in other cognitive domains. In general, the non-memory cluster was 
younger, had shorter disease duration, lower MMSE, were more often APOE e4 negative, and had more 
posterior and less hippocampal atrophy. Together this suggests that there are at least two different 
phenotypes of AD, with differences both in terms of clinical presentation, demographics, and brain 
changes. The study is strengthened by the fact that main findings were replicated in 4 independent cohorts. 
 
Major comments: 
 
1. This paper has already been revised. One of the revisions was a validation of the findings in the 
ADC subgroup with pathological CSF T-tau/AB42 ratio. However, in the copy that I have 
reviewed this result is only mentioned briefly in the discussion. I believe that an important 
limitation of this paper is the risk of clinical misdiagnosis of AD. The biomarker-based validation 
is therefore very important and needs to be thoroughly described in the results section. 
 
We are not sure what the reviewer means with ‘already revised’, because this paper has not been 
sent out for review before; we have however answered some questions on request of the editor 
before the manuscript was sent out for review. Among these considerations was an exploration of 
biomarker confirmed cases in our cohorts. Sufficient numbers of CSF biomarkers were only 
available for the ADC cohort. When we repeated clustering in the subset of biomarker confirmed 
ADC patients, we found comparable cognitive clusters, with similar demographic and 
neurobiological characteristics. On the reviewer’s suggestion, we have added these results to the 
manuscript (page 10).  
 
2. I think it is promising that you could replicate the main findings when restricting the analysis to 
the ADC cohort with an AD-pattern of CSF biomarkers. But to really address the question of 
possible misdiagnosis of subjects I think you need to report the percentages of people with 
pathological biomarkers in the different clusters and centres. For example, what was the 
percentage of pathological CSF Ab42 in memory and non-memory clusters in the different 
cohorts? The title of your paper implies that you are only testing patients with AD. I therefore 
think it is necessary to take every possible step to show that there was no systematic bias caused 
by clinical misdiagnosis. For example, was the percentage of normal CSF AB42 higher in the 
non-memory group in any cohort where this could be tested? 
 
We see the reviewer’s point on the misleading title and lack of biomarker confirmation. Since our 
study focused on clinical AD diagnosis (i.e. probable AD according to the NINCDS-ADRDA 
criteria[1]), we have tried to limit the expectation that our study is based on biomarker confirmed 
data and rephrased the title (page 1). In addition, we have summarized requested information in 
the manuscript (page 10), and provided requested data in table 1 and 2. Please note that for 
cohorts other than ADC, availability of CSF biomarkers was not optimal. 
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3. Another potential bias that you need to control for is differences in vascular pathology/white 
matter pathology between the different clusters. Please include data on for example white matter 
lesions and vascular risk factors and show how these differ between clusters. If one of the clusters 
has less prevalence of amyloid pathology but higher prevalence of white matter pathology there is 
a risk that clinical misdiagnosis affected the results. 
 
We compared cognitive clusters in terms of white matter hyperintensities in the ADC, ADNI, and 
DCN cohorts (not available for UCSF). No differences were found between the memory and non-
memory clusters (p > 0.05). We added results to tables 1 and 2.    
 
4. The discussion section largely reiterates the results, and should be expanded with details on how 
these novel findings relate to previous findings of clinical and pathological heterogeneity in AD. 
For example, there is a rich literature on co-pathologies in patients with a clinical AD diagnosis. 
To what degree can that help explain your findings? You could also incorporate more discussions 
about pathogenic mechanisms. You mention this very briefly ("different underlying disease 
anatomy") but I think the paper would really benefit from a discussion about how these different 
clinicopathological phenotypes may arise. 
 
We thank the reviewer for the opportunity to extend our discussion section (page 11-12). We think 
this has enriched our manuscript.  
 
 
Minor comments: 
 
1.  I agree with the authors that it was surprising that the non-memory cluster was so prevalent in 
ADNI. In fact, at 52 % it was even bigger than the memory cluster. You should therefore correct 
the sentence in the discussion which says that "In each cohort, the majority of patients belonged to 
the memory cluster". There is also a typo in section 3.3 where it says that "In the ADNI cohort, 
non-memory patients tended to be younger and less often APOE e4 negative". This should 
probably be "less often APOE e4 positive". 
 
We thank the reviewer for noticing and changed the text according to the suggestion (page 10, 
11).  
 
2. Depending on the results of this revision you can consider changing the title to highlight that you 
used a clinical AD diagnosis. 
 
We agree with the reviewer and rephrased the title (page 1), including the clinical diagnosis 
‘probable AD’ that we used as inclusion criterion [1]. 
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 RESEARCH IN CONTEXT  
1.Systematic review: Alzheimer’s disease (AD) is characterized by cognitive heterogeneity. We 
searched PubMed for clinical and neurobiological heterogeneity in AD profiles, and for data-driven 
approaches used to identify AD subtypes based on neuropsychological test scores. Several studies 
demonstrated the potential of clustering methods to identify cognitive AD subtypes. Identified 
subtypes showed distinct clinical characteristics. However none of the previous studies tested the 
generalizability of the cluster solutions, since those results were based on single-cohort studies. 
2. Interpretation: In four large AD cohorts, we consistently identified two cognitive clusters using 
Nonnegative Matrix Factorization of neuropsychological test scores. In each cohort one cluster most 
prominently showed memory-impairment, and the other cluster was relatively memory-spared. These 
clusters were associated with distinct clinical characteristics. 
3. Future directions: Future research should aim to further study the underlying biological disease 
mechanisms that cause a non-memory AD phenotype.  
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